Athenex (ATNX) Stock Price, News & Analysis

Company Overview

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.20 to $1.52
• 52-Week Range: N/A
• Volume: 1.88 million shs
• Average Volume: 194,316 shs
• Market Capitalization: $1.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ATNX Stock Analysis - Frequently Asked Questions

How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.08. The company earned $32.30 million during the quarter, compared to analyst estimates of $19.40 million. Athenex had a negative trailing twelve-month return on equity of 727.79% and a negative net margin of 86.31%.

When did Athenex IPO?

Athenex (ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager.

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Athenex investors own include TherapeuticsMD (TXMD), Meta Platforms (META), Sorrento Therapeutics (SRNE), NIO (NIO), NVIDIA (NVDA), Tesla (TSLA) and Ford Motor (F).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 6/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ATNX
• CIK: 1300699
• Web: www.athenex.com
• Phone: (716) 427-2950
• Fax: N/A
• Employees: 652
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($15.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$103.43 million
• Net Margins: -86.31%
• Pretax Margin: -95.92%
• Return on Equity: -727.79%
• Return on Assets: -44.44%

Debt

• Debt-to-Equity Ratio: 3.08
• Current Ratio: 1.09
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $102.82 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.07) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 8,660,000
• Free Float: 7,866,000
• Market Cap: $1.76 million
• Optionable: Optionable
• Beta: 1.36